Drospirenone and Ethinyl Estradiol
Active ingredient: Ethinyl Estradiol, Drospirenone
In short: Drospirenone and ethinyl estradiol tablet USP is indicated for use by females of reproductive potential to prevent pregnancy.
What is Drospirenone and Ethinyl Estradiol used for?
Drospirenone and ethinyl estradiol tablet USP is indicated for use by females of reproductive potential to prevent pregnancy.
âš Boxed warning (FDA's strongest warning)
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke .
Drospirenone and Ethinyl Estradiol dosage
Take one tablet by mouth at the same time every day. The failure rate may increase when pills are missed or taken incorrectly.
To achieve maximum contraceptive effectiveness, drospirenone and ethinyl estradiol tablets must be taken as directed, in the order directed on the blister pack. Single missed pills should be taken as soon as remembered.
Instruct the patient to begin taking drospirenone and ethinyl estradiol tablets either on the first day of her menstrual period (Day 1 Start) or on the first Sunday after the onset of her menstrual period (Sunday Start).
Day 1 Start
During the first cycle of drospirenone and ethinyl estradiol tablets use, instruct the patient to take one yellow drospirenone and ethinyl estradiol tablets daily, beginning on Day 1 of her menstrual cycle. (The first day of menstruation is Day 1.) She should take one yellow drospirenone and ethinyl estradiol tablet daily for 21 consecutive days, followed by one white to off-white tablet daily on Days 22 through 28. Drospirenone and ethinyl estradiol tablets should be taken in the order directed on the package at the same time each day, preferably after the evening meal or at bedtime with some liquid, as needed. Drospirenone and ethinyl estradiol tablets can be taken without regard to meals. If Drospirenone and ethinyl estradiol tablets are first taken later than the first day of the menstrual cycle, drospirenone and ethinyl estradiol tablets should not be considered effective as a contraceptive until after the first 7 consecutive days of product administration. Instruct the patient to use a non-hormonal contraceptive as back-up during the first 7 days. The possibility of ovulation and conception prior to initiation of medication should be considered.
Sunday Start
During the first cycle of drospirenone and ethinyl estradiol tablets use, instruct the patient to take one yellow drospirenone and ethinyl estradiol tablet daily, beginning on the first Sunday after the onset of her menstrual period. She should take one yellow drospirenone and ethinyl estradiol tablet daily for 21 consecutive days, followed by one white to off-white tablet daily on Days 22 through 28. Drospirenone and ethinyl estradiol tablets should be taken in the order directed on the package at the same time each day, preferably after the evening meal or at bedtime with some liquid, as needed. Drospirenone and ethinyl estradiol tablets can be taken without regard to meals. Drospirenone and ethinyl estradiol tablets should not be considered effective as a contraceptive until after the first 7 consecutive days of product administration. Instruct the patient to use a non-hormonal contraceptive as back-up during the first 7 days. …
How to take Drospirenone and Ethinyl Estradiol — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Counsel patients that cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and smoke should not use COCs.
Counsel patients that the increased risk of VTE compared to non-users of COCs is greatest after initially starting a COC or restarting (following a 4-week or greater pill-free interval) the same or a different COC.
Counsel patients about the information regarding the risk of VTE with DRSP-containing COCs compared to COCs that contain levonorgestrel or some other progestins.
Counsel patients that drospirenone and ethinyl estradiol tablets does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
Counsel patients on Warnings and Precautions associated with COCs.
Counsel patients that drospirenone and ethinyl estradiol tablets contains DRSP. Drospirenone may increase potassium. …
Warnings & precautions
Do not take this medicine if: Drospirenone and ethinyl estradiol tablet is contraindicated in females who are known to have or develop the following conditions:
Renal impairment
Adrenal insufficiency
A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:
â—‹ Smoke, if over age 35
â—‹ Have deep vein thrombosis or pulmonary embolism, now or in the past
â—‹ Have cerebrovascular disease
â—‹ Have coronary artery disease
â—‹ Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)
â—‹ Have inherited or acquired hypercoagulopathies
â—‹ Have uncontrolled hypertension
â—‹ Have diabetes mellitus with vascular disease
â—‹ Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35
Undiagnosed abnormal uterine bleeding
Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive
Liver tumor (benign or malignant) or liver disease
Use of Hepatitis C drug combinations containing ombitasvir, paritaprevir/ritonavir, with or without dasabuvir due to the potential for ALT elevations .
Stop drospirenone and ethinyl estradiol tablets if an arterial or venous thrombotic (VTE) event occurs.
Based on presently available information on drospirenone and ethinyl estradiol tablets, DRSP-containing COCs may be associated with a higher risk of venous thromboembolism (VTE) than COCs containing the progestin levonorgestrel or some other progestins. Epidemiologic studies that compared the risk of VTE reported that the risk ranged from no increase to a three-fold increase. …
Drospirenone and Ethinyl Estradiol side effects
The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling:
Serious cardiovascular events and stroke
Vascular events
Liver disease
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in practice.
The data provided reflect the experience with the use of drospirenone and ethinyl estradiol tablets (3 mg DRSP/0.03 mg EE) in the adequate and well-controlled studies for contraception (N=2,837). The US pivotal clinical study (N=326) was a multicenter, open-label trial in healthy women aged 18 to 35 who were treated for up to 13 cycles. The second pivotal study (N=442)was a multicenter, randomized, open-label comparative European study of drospirenone and ethinyl estradiol tablets vs. 0.150 mg desogestrel/0.03 mg EE conducted in healthy women aged 17 to 40 who were treated for up to 26 cycles.
The most common adverse reactions (≥ 2% of users) were: premenstrual syndrome (13.2%), headache/migraine (10.7%), breast pain/tenderness/discomfort (8.3%), nausea/vomiting (4.5%) abdominal pain/discomfort/tenderness (2.3%) and mood changes (depression, depressed mood, irritability, mood swings, mood altered and affect lability (2.3%). …
Drug interactions
Consult the labeling of all concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations.
Substances Diminishing the Efficacy of COCs
Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the effectiveness of COCs or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampin, topiramate and products containing St. John's wort. Interactions between oral contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure. Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with COCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability.
Substances Increasing the Plasma Concentrations of COCs
Co-administration of atorvastatin and certain COCs containing EE increase AUC values for EE by approximately 20%. Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. …
About this medicine
Drospirenone and ethinyl estradiol tablets USP, 3 mg and 0.03 mg, provide an oral contraceptive regimen consisting of 28 tablets that contain the ingredients specified for each tablet below:
21 yellow film-coated tablets each containing 3 mg DRSP and 0.03 mg EE
7 inert white to off-white tablets
The inactive ingredients in the yellow tablets are corn starch, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, pregelatinized starch, talc, titanium dioxide and yellow iron oxide. The inert white to off-white tablets contains corn starch, lactose monohydrate, magnesium stearate, and pregelatinized starch.
FDA approved dissolution test specifications differ from USP.
Drospirenone (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6a,7,8,9,10,11,12,13,14,15, 15a,16-hexadecahydro-10,13-dimethylspiro-[17H-dicyclopropa- [6,7:15,16]cyclopenta[a] phenanthrene-17,2'(5H)-furan]-3,5'(2H)-dione) is a synthetic progestational compound and has a molecular weight of 366.5 and a molecular formula of C
24H
30O
3. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 57d1d945-9fc9-4e79-e063-6294a90a738a. Read the full official label on DailyMed.